Skip to main
ACERW
ACERW logo

Acer Therapeutics Inc Warrant 2017-13.04.18 on Acer Therapeutcs (ACERW)

$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy ACERW Stock

About Acer Therapeutics Inc Warrant 2017-13.04.18 on Acer Therapeutcs (ACERW)

Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor ...read more
Market cap
Today's volume
Revenue (TTM)
Avg. daily volume
EBITDA (TTM)
Open
Price / earnings ratio
Today's range
Debt / equity
52 week range
5 year debt / equity
Beta (LTM)
Interest coverage
Dividend & yield— (—)
Current ratio
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

How to buy ACERW stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in ACERW stock

    Navigate to the Explore page. Then, type ACERW into the search bar. When you see ACERW stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased ACERW stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Buy ACERW Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.